Funded Project Details - FY2021
|Title:|| DC-HIL in cancer|
Ponciano D. Cruz
|Congressional District Code:
||Biomedical Laboratory R&D
|| January 2018 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Melanoma and other cancers continue to cause significant morbidity and mortality. Having discovered an immune regulator (DC-HIL) whose function can be manipulated to treat cancers, we will: (1) determine whether DC-HIL accounts for resistance to current cancer immunotherapy; (2) characterize the combination of mAb against immune targets that produces optimal treatment benefits; and (3) elucidate how blocking the DC-HIL ligand (syndecan-4) on T cells leads to better outcomes for cancer treatments...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.